Tenax Therapeutics offers a favorable risk/reward setup and a perfect earnings beat streak, but the underlying fundamentals remain weak and the large analyst upside estimate rests on thin, light coverage.
Thesis pillars
- High Asymmetry Small Cap Edge→Stable
- Perfect Earnings Beat Streak↓Deteriorating
- Weak Fundamentals Cash Burn→Stable
- +1 more pillar — see the Why tab for full reasoning
Tenax Therapeutics, Inc. (TENX) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $14.47, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: small number of product opportunities (levosimendan); Concentration risk — Counterparty: Orion Corporation (levosimendan licensor).
Tenax Therapeutics is a clinical-stage pharmaceutical company developing cardiopulmonary therapies, prioritizing oral levosimendan (TNX-103) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF) through two Phase 3 trials, LEVEL and LEVEL-2,... Read more
Hold if already holding. Not a fresh buy at $14.47, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: small number of product opportunities (levosimendan); Concentration risk — Counterparty: Orion Corporation (levosimendan licensor). Chart setup: No clear chart pattern; technical signals are mixed. Market cap $388M below $400M minimum. Not in investable universe. Score 5.6/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
About Tenax Therapeutics, Inc.
About Tenax Therapeutics, Inc.
Tenax Therapeutics is advancing two Phase 3 trials, LEVEL and LEVEL-2, of oral levosimendan (TNX-103) in pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF), a disease affecting an estimated 1.5 million people in the U.S. with no FDA-approved therapies; LEVEL-2, initiated in December 2025, plans to enroll approximately 540 patients. The company's second candidate, imatinib for pulmonary arterial hypertension, has been deprioritized in favor of levosimendan. Tenax reported a $56.4 million net operating loss in 2025 and held $97.6 million in cash as of December 31, 2025, following a $25.0 million private placement in March 2025 that supplemented roughly $100 million raised in August 2024.
Tenax has no approved products and generates no product revenue; its lead compound, levosimendan, is licensed exclusively from Orion Corporation under an agreement that requires tiered royalties on worldwide net sales plus milestone payments, including $10.0 million upon FDA approval, $5.0 million upon Japanese approval, and up to $45.0 million in additional sales-based milestones. Under a September 2025 amendment, Orion also agreed to supply Tenax with levosimendan active ingredient for manufacturing oral products, at a price described in low triple-digit thousands of dollars per order. Levosimendan itself is already approved intravenously in 60 countries for acutely decompensated heart failure, giving Tenax an established safety database even though the oral formulation and the PH-HFpEF indication remain unapproved anywhere. If no U.S. regulatory approval for a levosimendan product is granted by September 20, 2030, either Tenax or Orion can terminate the license.
Show full overview
Tenax's survival is tied to a small number of clinical outcomes rather than a broad portfolio: the 10-K states directly that the company's survival depends on its success with a small number of product opportunities, and with imatinib deprioritized, that now means levosimendan's LEVEL and LEVEL-2 Phase 3 results are effectively the whole company. Layered on top is a licensing dependency — Tenax does not own levosimendan outright but instead owes Orion Corporation royalties, regulatory milestones, and commercialization milestones under a license that could lapse in 2030 absent U.S. approval, meaning both the clinical and intellectual-property risk sit outside Tenax's full control at the same time.
See also: Healthcare · Biotechnology
From Tenax Therapeutics, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-24Recent Developments — Tenax Therapeutics, Inc.
Latest news
- NEWS Evercore ISI Group Initiates Coverage On Tenax Therapeutics with Outperform Rating, Announces Price Target of $39 — benzinga Jul 22, 2026
- NEWS Rivian Automotive, Tenax Therapeutics, Robinhood And Other Big Stocks Moving Higher On Thursday — benzinga Jul 2, 2026 positive
Generated 2026-07-25T09:22:36Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinesmall number of product opportunities (levosimendan)10-K Item 1A: 'We are limited in the number of products we can simultaneously pursue and therefore our survival depends on our success with a small number of product opportunities.'
- HIGHcounterpartyOrion Corporation (levosimendan licensor)10-K Item 1A: 'We may be required to make milestone and royalty payments to the licensor of the levosimendan intellectual property in connection with the development and commercialization of levosimendan, which could adversely affect the profitability of levosimendan, if approved.'
Material Events(8-K, last 90d)
- 2026-06-29Item 5.02LOWBoard approved amendments to employment agreements for Christopher Giordano, Thomas Staab, and Stuart Rich aligning their severance and change-in-control benefits with the company's newly adopted CIC and Severance Plans. Routine compensation amendment, not a departure.SEC filing →
- 2026-04-22Item 5.02LOWThomas R. Staab, II appointed Chief Financial Officer effective May 11, 2026, succeeding Interim CFO Thomas A. McGauley, who continues as principal financial/accounting officer through the Q1 2026 10-Q filing. Clean succession.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·2 ceiling hits
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $14.47, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: small number of product opportunities (levosimendan); Concentration risk — Counterparty: Orion Corporation (levosimendan licensor). Chart setup: No clear chart pattern; technical signals are mixed. Market cap $388M below $400M minimum. Not in investable universe. Target $30.23 (+108.9%), stop $13.51 (−7.1%), A.R:R 7.2:1. Score 5.6/10, moderate confidence.
Take-profit target: $30.23 (+108.1% upside). Target $30.23 (+108.9%), stop $13.51 (−7.1%), A.R:R 7.2:1. Stop-loss: $13.51.
Concentration risk — Pipeline: small number of product opportunities (levosimendan); Concentration risk — Counterparty: Orion Corporation (levosimendan licensor); Market cap $388M below $400M minimum.
Tenax Therapeutics, Inc. trades at a P/E of N/A (forward -10.6). TrendMatrix value score: 9.0/10. Verdict: Hold.
12 analysts cover TENX with a consensus score of 4.3/5. Average price target: $35.
What does Tenax Therapeutics, Inc. do?Tenax Therapeutics is a clinical-stage pharmaceutical company developing cardiopulmonary therapies, prioritizing oral...
Tenax Therapeutics is a clinical-stage pharmaceutical company developing cardiopulmonary therapies, prioritizing oral levosimendan (TNX-103) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF) through two Phase 3 trials, LEVEL and LEVEL-2, while it has deprioritized a Phase 3 trial of imatinib for pulmonary arterial hypertension. The company has no approved products or product revenue, licenses its lead compound levosimendan exclusively from Orion Corporation, and reported a $56.4 million net operating loss in 2025 with $97.6 million in cash as of December 3